U.K. officials are finally taking the wraps off their new drug-pricing plan. The pharma industry has been waiting for the update to go public--but branded drugmakers are likely to wish they could wait longer. Under the new 5-year agreement, drugmakers will suffer new spending caps beginning next year.
Irish CRO Venn Life Sciences has agreed to trade nearly $1 million of stock for Germany's CRM Clinical Trials, a move that will stretch its reach into one of Europe's largest research markets.
Vetter, the Germany-based company that specializes in contract aseptic filling, is preparing for a significant expansion as demand for injectable drugs grows globally.
The German price watchdog has found yet another drug it can't warm up to. This time it's Shire's new ADHD drug Vyvanse, known as Elvanse in Germany.
Germany's pricing agency has rejected offerings right and left, and drugmakers say it is getting increasingly hard to make any money in the country. But it turns out that at the same time it has been turning its back on some players, the government has been cutting a break to financially struggling German companies.
Eisai is fed up with Germany's pricing authority. So fed up, in fact, that it plans to stop selling its new seizure drug there. It's just the latest example of a pharma company loath to market its meds in Germany, now that cost regulators have raised new hurdles.
Expect Edwards Lifesciences' aggressive and increasingly hard-core heart valve patent battle with Medtronic to get worse in the coming weeks. An industry analyst predicts that a German court will issue an injunction preventing Medtronic from selling its CoreValve transcatheter aortic valve replacement in that country. And continued legal action is advancing in the U.S.
As Bloomberg reports, Germany's Der Spiegel has ferreted more details about drug research in Soviet-era East Germany, where pharma groups tied to some of the biggest names in the industry reportedly benefited from cheap clinical trials before the fall of the Berlin Wall.
OrbusNeich Medical called the cops on Boston Scientific in Germany in a nasty escalation of their ongoing stent patent dispute.
Drugmakers, livid with German pricing gatekeepers for turning down so many new drugs, now face a strategy that is sure to ratchet up their anger to the boiling point.